Fiche publication
Date publication
janvier 2015
Journal
La Revue de medecine interne
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GENY Bernard
Tous les auteurs :
Vogel T, Geny B, Kaltenbach G, Lang PO
Lien Pubmed
Résumé
Prescribing anticoagulant therapy when the CHA₂DS₂-VASc score is ≥ 1 prevents strokes secondary to non-valvular atrial fibrillation (AF). However, it is important to remember that whether the aged population has the highest risk of stroke in case of AF, under anticoagulant therapy this population is also at the highest risk of bleeding. Vitamin K antagonists were for decades the molecules of reference with benefits even after 75 years of age. The direct oral anticoagulants have overcome the biological constraints inherent to monitoring vitamin K antagonists and provide a more stable pharmacological action with a limited number of drug-drug interactions. However, the widespread use of these molecules in the older population remains controversial. In this review article, indications and modalities of administration of anticoagulant therapy in the elderly will be detailed and discussed on the basis of the most recent recommendations proposed in particular by the European Society of Cardiology. Particular attention will be paid to new oral anticoagulant therapies compared with vitamin K antagonists and antiplatelet agents.
Mots clés
Antivitamin K, Antivitamine K, Atrial fibrillation, Elderly, Fibrillation atriale, New oral anticoagulant, Nouveaux anticoagulants oraux, Sujet âgé
Référence
Rev Med Interne. 2015 Jan;36(1):22-30
